KAPA (Kairos Pharma Ltd) קצב צמיחת רווח למניה בשנה הנוכחית

Partnerships with universities minimize R&D costs, strengthening the capital of Kairos Pharma Ltd. This annual EPS change chart visualizes this resilience, where -23.50 represents the current metric level. Developing drugs to combat tumor resistance restores therapy efficacy, while strict FDA oversight and patent protection create insurmountable barriers for new entrants.
פילוחים אנליטיים ודוחות נתונים של חברת Kairos Pharma Inc (KAPA)

Kairos Pharma Ltd (KAPA) operates in an isolated biotechnology segment where demand for pharmaceuticals remains independent of macroeconomic shocks. This indicator captures the percentage deviation of current earnings per share from the same value last year. Growth in this metric confirms the effectiveness of innovation capitalization and the stability of cash flows. For the investor, this serves as a signal of the asset's defensive qualities. The price action on the annual EPS growth chart visualizes the business scaling rates.